GLP-1semaglutideliraglutidetype 2 diabetessustain 6leader

Pooled GLP-1 trial analysis finds little covariate-driven treatment heterogeneity

Causal forest analysis of 13,670 patients from SUSTAIN 6, PIONEER 6 and LEADER ranked baseline HbA1c highest among effect modifiers, but explained variation was small.

By Maren Holt · Senior Reporter, GLP-1

Oct 19 20:00 ETSource: American journal of epidemiology

The wire

01Researchers pooled SUSTAIN 6 (n=3,297), PIONEER 6 (n=3,183) and LEADER (n=9,340) to 13,670 type 2 diabetes patients and tested treatment effect heterogeneity on HbA1c, BMI and blood pressure endpoints.
02Baseline HbA1c ranked highest among candidate effect modifiers and kidney function next, but the authors conclude the average treatment effect is a reasonable summary for most patients.
03The analysis is exploratory and post hoc across trials of semaglutide and liraglutide versus placebo, so it does not identify prospectively actionable responder subgroups.

From the source

Exploring heterogeneous treatment effects for GLP-1 receptor agonists in patients with type 2 diabetes
American journal of epidemiology · 2026 Oct 20 · Keele L, Bonvini M, Storås AM et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42901472/